Petosemtamab (MCLA-158)
1L PD-L1+ r/m Head and Neck Squamous Cell Carcinoma (with pembrolizumab)
Key Facts
About Merus
Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.
View full company profileAbout Merus
Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.
View full company profileAbout Merus
Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.
View full company profileAbout Merus
Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.
View full company profileAbout Merus
Merus is a clinical-stage biotech focused on closing in on cancer by discovering and developing novel multispecific antibody therapeutics. The company's core asset is its proprietary Multiclonics® platform, which enables the creation of full-length, human IgG bispecific and trispecific antibodies with manufacturing and pharmacokinetic profiles akin to conventional monoclonal antibodies. Merus has built a robust, wholly-owned and partnered clinical pipeline, with its lead candidate, petosemtamab, in Phase 3 development for head and neck cancer. The company's recent acquisition by and integration into Genmab represents a pivotal strategic shift, providing enhanced resources and a broader platform to accelerate its ambitious oncology programs.
View full company profile